SCHEMBL9892937

SCHEMBL9892937

CCC1CCN1C(=O)C1CCC(F)(F)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.39
CNR2 P34972 2/20 0.37
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
EPHX2 P34913 1/20 0.35
MAPT P10636 3/20 0.34
SMYD3 Q9H7B4 2/20 0.33
HCRTR2 O43614 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
IL1B P01584 1/20 0.32
P2RX7 Q99572 1/20 0.32
LMNA P02545 2/20 0.32
KDM4E B2RXH2 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.31
GRM5 P41594 1/20 0.31
HTR1A P08908 1/20 0.31
DRD2 P14416 1/20 0.31
DRD4 P21917 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9893108 0.83 HSD11B1 (0.36) HSD11B1CNR2NR1H2NR1H3EPHX2
SCHEMBL9893119 0.79 PIK3CD (0.42) HSD11B1CNR2NR1H2NR1H3MAPT
SCHEMBL9892998 0.79 PIK3CD (0.42) HSD11B1CNR2NR1H2NR1H3MAPT
SCHEMBL9893039 0.78 HSD11B1 (0.38) HSD11B1CNR2NR1H2NR1H3MAPT
SCHEMBL13015212 0.75 PIK3CD (0.40) HSD11B1CNR2NR1H2NR1H3EPHX2
SCHEMBL9891501 0.74 CNR2 (0.41) HSD11B1CNR2NR1H2NR1H3EPHX2
SCHEMBL20713023 0.74 MAPT (0.46) HSD11B1MAPTALDH1A1GAALMNA
SCHEMBL3434946 0.73 CNR2 (0.40) HSD11B1CNR2NR1H2NR1H3EPHX2
SCHEMBL3434949 0.73 CNR2 (0.40) HSD11B1CNR2NR1H2NR1H3EPHX2
SCHEMBL9893109 0.72 CNR2 (0.45) HSD11B1CNR2NR1H2NR1H3EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 HSD11B1 3407/4885CNR2 1/4885NR1H2 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.